Epidermal Growth Factor Receptor Antagonist [EPC]: Side Effects & Safety Data for 3 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Epidermal Growth Factor Receptor Antagonist [EPC] includes 3 drugs with a combined 25,796 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
3
Drugs in Class
25,796
Combined Reports
All Epidermal Growth Factor Receptor Antagonist [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| CETUXIMAB | ERBITUX | 14,553 | 2,104 | 5,157 | 14.5% |
| PANITUMUMAB | Vectibix | 10,876 | 1,666 | 3,121 | 15.3% |
| NECITUMUMAB | Portrazza | 367 | 69 | 131 | 18.8% |
Common Side Effects in Epidermal Growth Factor Receptor Antagonist [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Rash | 2,323 | 186 |
| Off label use | 2,124 | 340 |
| Diarrhoea | 2,012 | 270 |
| Neutropenia | 1,527 | 174 |
| Death | 1,305 | 1,305 |
| Nausea | 1,292 | 144 |
| Dermatitis acneiform | 1,227 | 117 |
| Skin toxicity | 982 | 53 |
| Fatigue | 974 | 134 |
| Decreased appetite | 962 | 156 |